nach oben

Erschienen in:

01.06.2019 | Case report

Vedolizumab

Fatigue and exercise intolerance secondary to tachycardia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study involving 25 children receiving vedolizumab from 2015 till 2018, a child [sex and exact age not stated] was described, who developed fatigue and exercise intolerance due to tachycardia following treatment with IV infusion of vedolizumab for paediatric inflammatory bowel disease [dosage, duration of treatment to reaction onset and outcome not stated]. …

Aardoom MA, et al. Trough levels and efficacy of Vedolizumab in refractory PIBD patients. Journal of Pediatric Gastroenterology and Nutrition 68 (Suppl. 1): 486-487 abstr. G-P-332, May 2019. Available from: URL: http://doi.org/10.1097/MPG.0000000000002403 [abstract] - Netherlands

Titel: Vedolizumab
Fatigue and exercise intolerance secondary to tachycardia: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-64152-x

Springer Medizin

Vedolizumab

Fatigue and exercise intolerance secondary to tachycardia: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Antineoplastics

Antineoplastics/folinic acid

Anakinra

Mirtazapine

Warfarin

Infliximab

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Antineoplastics

Antineoplastics/folinic acid

Anakinra

Mirtazapine

Warfarin

Infliximab